Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR2C | P28335 | 6/20 | 0.45 |
| ▸ | HTR2A | P28223 | 2/20 | 0.45 |
| ▸ | HTR7 | P34969 | 2/20 | 0.45 |
| ▸ | HTR6 | P50406 | 2/20 | 0.45 |
| ▸ | HSD11B1 | P28845 | 2/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8711234 | 0.90 | HTR2C (0.48) | HTR2CHTR2AHTR7HTR6 | |
| SCHEMBL8716553 | 0.87 | HSD11B1 (0.55) | HTR2CHTR2AHTR7HTR6HSD11B1 | |
| SCHEMBL8710890 | 0.87 | MEN1 (0.51) | HTR2CHTR2AHTR7HTR6 | |
| Fumaric Acid SCHEMBL9232874 | 0.86 | HTR2C (0.44) | HTR2CHTR2AHTR7HTR6 | |
| SCHEMBL8711675 | 0.86 | HTR2A (0.51) | HTR2CHTR2AHTR7HTR6 | |
| SCHEMBL8711375 | 0.85 | PTGIR (0.51) | HTR2CHTR2AHTR7HTR6HSD11B1 | |
| SCHEMBL8713474 | 0.84 | ACHE (0.52) | HTR2CHTR2AHTR7HTR6 | |
| SCHEMBL9233342 | 0.82 | HTR2A (0.48) | HTR2CHTR2AHTR7HTR6 | |
| SCHEMBL8711345 | 0.82 | HSD11B1 (0.52) | HTR2CHTR2AHTR7HTR6HSD11B1 | |
| SCHEMBL8710857 | 0.82 | SMN1; SMN2 (0.52) | HTR2CHTR2AHTR7HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-5728835-A | HYPOTENSIVE AGENTS; ANTIISCHEMIC AGENTS | TOA EIYO, LTD. (JP) | 1998-03-17 | — | — | US | disclosed |
| EP-0661266-A1 | Substituted cyclic amine compounds as 5HT2 antagonists | TOA EIYO LTD. (JP) | 1995-07-05 | — | — | EP | disclosed |